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Word count of the abstract: 238 
Objective: To investigate variations of PSA levels among men with an initial normal PSA level 
in the PLCO Study. 
Methods: Data were extracted from the PLCO study dataset on all men in the intervention 
arm, with two tests performed in a period of less than two years and with an initial result of 
the first test below 4 ng/mL. The range of variation between first and second tests was 
computed. Risks of cancer stratified on Gleason score were computed using logistic 
regression. 
Results: 31,286 men had two PSA tests within two years and with an initial value below 4 
ng/mL. From the first to second test, the median variation of PSA levels was 3.4% (IQR: -15%; 
+26%). The variation in PSA value was not associated with the delay between first and 
second test (p=0.36), with age (p=0.16), BMI (p=0.41) and race (p=0.12).  
2,781 prostate cancers were diagnosed during follow-up. Adjusting for age and initial PSA 
level, the risk of prostate cancer increased linearly with increasing PSA level at second test, 
with an odds ratio of 1.079 (95% CI (1.058, 1.101)) for each percent increase in PSA level. 
However, the variation in PSA was not associated with a higher Gleason score (p<0.95 for 
ůĞǀĞůǀĂƌŝĂƚŝŽŶƐŝŶĐĂŶĐĞƌŽĨ'ůĞĂƐŽŶƐĐŽƌĞA? ?ǀƐA? ? ?  
Conclusions: While an increase in PSA level over time is associated with increased risk of 
prostate cancer, this association is not related to more aggressive tumors. 
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Word count: 2,572 
Introduction 
The risk of prostate cancer is directly related to the level of total prostate specific 
antigen (tPSA) measured in blood 
1
. PSA is being considered the best biochemical marker for 
prostate cancer and is widely used for early detection, diagnosis and monitoring. But the 
evaluation of use of PSA in screening activities showed that PSA testing induced substantial 
over-diagnosis of prostate cancer, mainly due to poor specificity of the test.  
/ƚ ŝƐ ŬŶŽǁŶ ƚŚĂƚ ƐĞƌŝĂů ŵĞĂƐƵƌĞŵĞŶƚƐ ŽĨ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ƚW^ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ? ĞǀĞŶ
when all results are obtained by a single method, may fluctuate with higher amplitude than 
can be explained by ƚŚĞĂƐƐĂǇ ?ƐĂŶĂůǇƚŝĐĂůǀĂƌŝĂƚŝŽŶ2-4. This reflects an additional component 
of intra-individual or within-subject variation, known as biological variation. 
Variation of PSA level could lead to unnecessary biopsies if based on a single 
measurement. It has been shown in the Polyp Prevention Trial that, following an initial 
abnormal PSA level, an important proportion of men returned to normal PSA level at the 
subsequent visit (26% for an initial value above 2.5 ng/ml and 30% for an initial value above 
4 ng/ml) 
5
. 
The normal variation of PSA level has been evaluated in the past in few studies, and 
already an important variation in men has been reported. In a series of eight men with 
adenocarcinoma of the prostate, the maximum variation above and below the mean were of 
19.3% and 17.7% 
6
.  
The biological variation of tPSA has implications for screening and diagnosis. Single 
measurements may not be sufficiently precise for screening and diagnosis. Replicate samples 
and calculation of the mean concentration may improve precision by reducing the 
Highlighted Manuscript (without author identifiers)
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dispersion. Monitoring of tPSA requires an estimate of either the change needed for 
significance or, alternatively, of the significance of the change. 
However, subsequently there have been investigations of variation in tPSA from most 
recent sources (e.g. 
7-10
) without any real conclusions being drawn and a lack of cohesion 
between findings and hypotheses investigated. 
Therefore, variations of PSA levels were studied in men participating in the 
intervention arm of the PLCO Study 
11
 and with an initial PSA level below 4 ng/mL. This 
database has a major advantage of standardization of the follow-up of men and a good 
quality monitoring of patients and follow-up. 
 
Material and methods 
Data were extracted from the PLCO study dataset of August 2012 on all of the 38,340 
men in the intervention arm. These Cancer Data Access System (CDAS) datasets are slightly 
more up to date than the original report at 13 years of follow-up with reclassification of 
some events based on updated data and further review, and this could explain slight 
discrepancies in numbers from this report as compared to the article of Andriole et al (2012) 
11
. 
All potential PSA measurements were extracted for each man, so these could be part 
of the annual test in the intervention or any additional test performed during follow-up. We 
included men who received two valid PSA tests performed in a period of less than two years, 
thus excluding 576 individuals with greater delay between two tests. As our objective was 
the evaluation of PSA variability in men considered having an initial normal test, we excluded 
2577 men who did have an initial abnormal with a PSA value of 4 ng/ml or above. Because 
the present study investigated change in PSA, 1597 individuals with only one PSA test and 
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2343 individuals with no PSA measurement were also excluded. Some of these exclusion 
criteria could be overlapping. 
Unlike other reports on the subject 
5
, the analysis was restricted to the first two tests 
and did not include any further tests. This decision was based on the fact that including more 
tests for men could introduce a bias in the analysis. For example, men with more tests could 
have a reduced global variation because of smoothing effect of combining more information. 
In addition, there could be a differential risk of cancer: men with more tests could be under 
more surveillance because more at risk of cancer (for example because of a family history); 
alternatively men with more tests could be at a lower risk of cancer because of prolonged 
latency, and men without cancer have necessarily more PSA tests than men with a cancer 
diagnosed few years after inclusion.  
The prostate cancer incidence data for this study were collected up to 31 December 
2009, and any occurrence of prostate cancer was included. Data on Gleason score were 
extracted and classified with lesions less than 7 versus tumors with a Gleason score of 7 or 
more. 
The variation of PSA level between the first and second test was expressed in 
percentage of variation relative to baseline value: [Variation = (Second PSA-First PSA)/ First 
PSA]. This computation allows for the baseline value to be taken into account. Hence a 
change from 1 ng/ml to 1.5 ng/ml would be a 50% variation similarly to a change from 2 
ng/ml to 3 ng/ml would be a 50% variation. It then gives less variation for a change from 3 to 
3.5 than from a change from 1 to 1.5. To describe the overall variation of PSA measured 
between first and second measurement, either positive or negative, the absolute value of 
variation was also reported as the total variation. 
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Test of the association between PSA level at baseline and other factors was 
conducted in a bivariate analysis with chi-square test. 
The evaluation of the impact of individual factors, as well as baseline PSA value, on 
the total variation was performed with a multivariate linear regression. The impact of age, 
BMI, tobacco smoking, delay between first and second test, initial PSA value was estimated. 
Risks of prostate cancer according to PSA level variations using logistic regression 
were also computed. This model was adjusted for age at entry in the trial, initial PSA value 
and variation in PSA between first and second test. 
All analyses were conducted with SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). 
 
Results 
Among the 38,340 men participating to the intervention arm, 31,286 men had two 
PSA tests within two years and with an initial value below 4 ng/mL, a level widely taken as 
the upper limit of normal.  
The PSA level measured in the first test was significantly (p<0.0001 chi-square test) 
associated with age (Table 1). 
The association of baseline PSA value was also found for BMI (p<0.0001 chi-square 
test), for which lower PSA values were observed for obese patients (median 0.94 ng/ml 
among the 7,337 obese patients: BMI above 30 kg/m
2
) and for overweight men (median 1.06 
ng/ml among the 15,392 overweight patients: BMI between 25 and 30 kg/m
2
), as compared 
to men with normal BMI (median 1.11 ng/ml among the 7,880 patients with normal weight: 
BMI between 18.5 and 25 kg/m
2
). Tobacco smoking was also significantly associated with a 
lower PSA level at baseline (p<0.0001 chi-square test): the median PSA for current smokers 
was 1.01 ng/ml, for former smokers the median PSA was 1.01 ng/ml, as compared to never 
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smokers which PSA level was 1.08 ng/ml. The effect of tobacco smoking was independent of 
BMI as in an linear regression of PSA value at baseline adjusted on BMI status, current 
smoker had on average 0.10 ng/ml (95%CI (-0.14, -0.07)) less than never smokers. Race was 
not significantly associated with PSA level at baseline (p=0.09 when comparing the six 
different ethnic groups and p=0.25 when comparing PSA levels between non-Hispanic white 
men versus non-Hispanic black men).  
The median duration between first and second test was 344 days (interquartile range 
[IQR]: 324; 365). From the first to second test, the median variation of PSA levels was 3.4% 
(IQR: -15%; +26%) indicating that for a quarter of men the PSA level at second test was 15% 
lower than at first test, and that for another quarter of men the PSA level at second test was 
26% higher than at first test (figure 1). 
In other words, for half of men, the change in PSA level between the first and the 
second test exceeded 20%. The variation in PSA value was not significantly associated with 
the delay between first and second test (p=0.36 GLM model), with age (p=0.16), with BMI 
(p=0.41) and with race (p=0.12). In terms of total variation, the PSA value varied either 
positively or negatively by an average of 18% between first and second test (interquartile 
range: 9.2%, 36.8%). 
In a multivariate model of the variation of PSA, older age was significantly associated 
with higher variation in PSA between first and second test. In addition the baseline value of 
PSA was strongly associated with total variation: lower initial value of PSA tended to be 
associated with greater total variation (table 2). 
2,781 prostate cancers were diagnosed during follow-up. Adjusting for age and initial 
PSA level, the risk of prostate cancer increased linearly with increasing PSA level at second 
test, with an odds ratio (OR) of 1.079 (95% CI 1.058-1.101) for each % increase in PSA level. 
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Table 3 shows the distribution of prostate cancer cases by variation of PSA level between 
first and second test. 
However, the variation in PSA was not associated with a higher Gleason score 
 ?ƉA? ? ? ? ?ĨŽƌůĞǀĞůǀĂƌŝĂƚŝŽŶƐŝŶĐĂŶĐĞƌŽĨ'ůĞĂƐŽŶƐĐŽƌĞA? ?ǀƐA? ?ŝŶĂůŽŐŝƐƚŝĐƌĞŐƌĞƐƐŝŽŶŵŽĚĞů
adjusting for age and baseline PSA value). Compared to men with decrease or no change in 
PSA level over time, men with variations in level of 50% or more had a 4.2 (95% CI 2.8-6.2) 
greater risk to be diagnosed with a lesion having a Gleason score of 5 or less, a 2.0 (95% CI 
1.7-2.4) greater risk to be diagnosed with a cancer of GleĂƐŽŶƐĐŽƌĞA? ?ďƵƚďĞůŽǁ ? ?ĂŶĚĂ
2.5 (95% CI 1.7- ? ? ? ?ŐƌĞĂƚĞƌƌŝƐŬƚŽďĞĚŝĂŐŶŽƐĞĚǁŝƚŚĂĐĂŶĐĞƌŽĨ'ůĞĂƐŽŶƐĐŽƌĞA? ? ? 
 
Discussion 
In one quarter of men with an initial PSA level less than 4 ng/mL, the level of a 
second PSA test performed on average one year later will be 20% lower, while for another 
quarter of men it will be 20% higher. While an increase in PSA level over time is associated 
with increased risk of prostate cancer, this association seems stronger for cancers of low 
Gleason score than for potentially more aggressive cancers. 
Boddy et al (2004) found in a series of 14 patients with benign prostatic biopsy and 
an initial PSA level below 4 ng/ml that the coefficient of variation of PSA was 14.1% 
12
. This 
figure is in line with our observation of an average coefficient of variation of 18.8%. 
A study focusing on PSA in relation to prostate volume found a yearly increase of PSA 
associated with PSA baseline value 
13
. While this report also found that the initial PSA level 
was an important factor, lower values were found to be associated with greatest variability. 
As Nichols et al (2012) used a different metric, the variation of PSA expressed as the 
difference in ng/ml per year, this metric was also applied to the PLCO dataset. However, the 
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findings remained unchanged with greater variation observed for the lower values of PSA at 
baseline. 
The initial PSA level was lower among obese and overweight men as reported in 
previous studies 
14,15
. In a study conducted in healthy men, free of prostate cancer, in 
Washington State, the geometric mean of PSA was 1.18, 1.12, and 0.94 for respectively 
normal, overweight and obese men 
14
. These levels of PSA by obesity status were also 
observed in this report. Wright et al reported that this association was however partially 
confounded with use of aspirin and non-steroidal anti-inflammatory drugs (NSAID) 
14
 which 
we could not evaluate in these data. We found that further changes in PSA over time were 
not associated with BMI level. 
Ethnicity is a factor associated with access to care and PSA testing is not spared from 
this inequality. In men with high PSA level, fewer non-Hispanic black men would conduct a 
repeated PSA test as compared to non-Hispanic white, in particular for those not in the age 
eligible for Medicare (less than 65) 
16
. However, when adjusting for age, baseline PSA and 
other factors, we did not found an association between change in PSA level and ethnicity as 
we could have expected that if non-Hispanic black men had fewer tests. As the PLCO study 
was restricted to men with two tests within two years and in the intervention arm of the 
PLCO study, and because PLCO study is a randomized trial, these could have selected the 
populations and reduced the impact of inequality of access to care by ethnic group. 
In the PCPT study, the level of PSA was further related with severity of the disease. 
Prostate cancer with a Gleason score of 7 or above were 40 % with a PSA above 4 ng/ml, as 
compared to 21 % for those with a Gleason score below 7. Even among those with a PSA 
below 4 ng/ml this association remained: 60 % of prostate cancer with a Gleason score of 7 
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or above being above 2 ng/ml as compared to 35% of those with a Gleason score less than 7 
1
. 
While we demonstrated that an elevated PSA provided an increasing risk of prostate 
cancer, the results from the PLCO study are in contradiction with the PCPT study, as we 
found that the initial level of PSA was unrelated to the severity of disease. 
Our study has potential limitations. First, a strict selection was used with only men 
with two tests within two years and no initial value of PSA greater than 4ng/ml. However, 
this represented 81.6% of the initial sample and therefore a strong bias is unlikely. A 
contamination by previous PSA tests could have created a bias in the evaluation of PSA 
variation, however the PLCO study excluded men with more than one PSA blood test in the 
previous three years. The PLCO study design adds also some limitation but also bring major 
advantages for the present research. On one hand, participants to PLCO study constitutes, as 
for any prospective study, a selected population with higher levels of education, lower 
history of chronic disease. Hence, variations of PSA between two test could be slightly 
different in the general population. On the other hand, this design enable to investigate 
variation of PSA in an homogeneous population which received regular opportunity to take a 
PSA test. Other design conducted in population would have been confronted to greater 
biases such a self-selection for the number of tests, intervals between tests, all these related 
ƚŽŝŶĚŝǀŝĚƵĂů ?ƐĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐƐƵĐŚĂƐƉĞƌĐĞƉƚŝŽŶŽĨƌŝƐŬ ?ŚĞĂůƚŚƐƚĂƚƵƐ ?ƐŽĐŝŽ-economic level, 
etc. 
Our study supports the idea that PSA testing cannot be considered as a perfect 
marker of prostate cancer risk. This weakness is inherent to PSA as it measures a 
characteristic of the prostate which is the release of an antigen in the blood. PSA is also a 
good marker of other prostate features, such as prostatic volume 
17
 and inflammation 
18
. 
 9 
 
Variation in PSA was not associated with higher Gleason score. This observation is in 
agreement with the lack of effectiveness of PSA Velocity above PSA alone which was 
illustrated by several studies 
19
. 
PSA alone at low values does not seem to be a good indicator of risk of prostate 
cancer as it does not help to differentiate aggressive versus indolent tumors. The use of PSA 
density has been suggested to provide further discriminant properties 
20
, but this measure is 
still not demonstrated as capable of identifying aggressive tumors. 
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Figure legends 
 
Figure 1. Distribution of the percentage variation of PSA level between first and second 
measurement in the PLCO study. The blue curve is a kernel density estimation with 
bandwidth=0.6. 
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Word count: 2,572 
Introduction 
The risk of prostate cancer is directly related to the level of total prostate specific 
antigen (tPSA) measured in blood 
1
. PSA is being considered the best biochemical marker for 
prostate cancer and is widely used for early detection, diagnosis and monitoring. But the 
evaluation of use of PSA in screening activities showed that PSA testing induced substantial 
over-diagnosis of prostate cancer, mainly due to poor specificity of the test.  
/ƚ ŝƐ ŬŶŽǁŶ ƚŚĂƚ ƐĞƌŝĂů ŵĞĂƐƵƌĞŵĞŶƚƐ ŽĨ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ƚW^ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ? ĞǀĞŶ
when all results are obtained by a single method, may fluctuate with higher amplitude than 
can be explained by ƚŚĞĂƐƐĂǇ ?ƐĂŶĂůǇƚŝĐĂůǀĂƌŝĂƚŝŽŶ2-4. This reflects an additional component 
of intra-individual or within-subject variation, known as biological variation. 
Variation of PSA level could lead to unnecessary biopsies if based on a single 
measurement. It has been shown in the Polyp Prevention Trial that, following an initial 
abnormal PSA level, an important proportion of men returned to normal PSA level at the 
subsequent visit (26% for an initial value above 2.5 ng/ml and 30% for an initial value above 
4 ng/ml) 
5
. 
The normal variation of PSA level has been evaluated in the past in few studies, and 
already an important variation in men has been reported. In a series of eight men with 
adenocarcinoma of the prostate, the maximum variation above and below the mean were of 
19.3% and 17.7% 
6
.  
The biological variation of tPSA has implications for screening and diagnosis. Single 
measurements may not be sufficiently precise for screening and diagnosis. Replicate samples 
and calculation of the mean concentration may improve precision by reducing the 
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dispersion. Monitoring of tPSA requires an estimate of either the change needed for 
significance or, alternatively, of the significance of the change. 
However, subsequently there have been investigations of variation in tPSA from most 
recent sources (e.g. 
7-10
) without any real conclusions being drawn and a lack of cohesion 
between findings and hypotheses investigated. 
Therefore, variations of PSA levels were studied in men participating in the 
intervention arm of the PLCO Study 
11
 and with an initial PSA level below 4 ng/mL. This 
database has a major advantage of standardization of the follow-up of men and a good 
quality monitoring of patients and follow-up. 
 
Material and methods 
Data were extracted from the PLCO study dataset of August 2012 on all of the 38,340 
men in the intervention arm. These Cancer Data Access System (CDAS) datasets are slightly 
more up to date than the original report at 13 years of follow-up with reclassification of 
some events based on updated data and further review, and this could explain slight 
discrepancies in numbers from this report as compared to the article of Andriole et al (2012) 
11
. 
All potential PSA measurements were extracted for each man, so these could be part 
of the annual test in the intervention or any additional test performed during follow-up. We 
included men who received two valid PSA tests performed in a period of less than two years, 
thus excluding 576 individuals with greater delay between two tests. As our objective was 
the evaluation of PSA variability in men considered having an initial normal test, we excluded 
2577 men who did have an initial abnormal test with a PSA value of 4 ng/ml or above. 
Because the present study investigated change in PSA, 1597 individuals with only one PSA 
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test and 2343 individuals with no PSA measurement were also excluded. Some of these 
exclusion criteria could be overlapping. 
Unlike other reports on the subject 
5
, the analysis was restricted to the first two tests 
and did not include any further tests. This decision was based on the fact that including more 
tests for men could introduce a bias in the analysis. For example, men with more tests could 
have a reduced global variation because of smoothing effect of combining more information. 
In addition, there could be a differential risk of cancer: men with more tests could be under 
more surveillance because more at risk of cancer (for example because of a family history); 
alternatively men with more tests could be at a lower risk of cancer because of prolonged 
latency, and men without cancer have necessarily more PSA tests than men with a cancer 
diagnosed few years after inclusion.  
The prostate cancer incidence data for this study were collected up to 31 December 
2009, and any occurrence of prostate cancer was included. Data on Gleason score were 
extracted and classified with lesions less than 7 versus tumors with a Gleason score of 7 or 
more. 
The variation of PSA level between the first and second test was expressed in 
percentage of variation relative to baseline value: [Variation = (Second PSA-First PSA)/ First 
PSA]. This computation allows for the baseline value to be taken into account. Hence a 
change from 1 ng/ml to 1.5 ng/ml would be a 50% variation similarly to a change from 2 
ng/ml to 3 ng/ml would be a 50% variation. It then gives less variation for a change from 3 to 
3.5 than from a change from 1 to 1.5. To describe the overall variation of PSA measured 
between first and second measurement, either positive or negative, the absolute value of 
variation was also reported as the total variation. 
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Test of the association between PSA level at baseline and other factors was 
conducted in a bivariate analysis with chi-square test. 
The evaluation of the impact of individual factors, as well as baseline PSA value, on 
the total variation was performed with a multivariate linear regression. The impact of age, 
BMI, tobacco smoking, delay between first and second test, initial PSA value was estimated. 
Risks of prostate cancer according to PSA level variations using logistic regression 
were also computed. This model was adjusted for age at entry in the trial, initial PSA value 
and variation in PSA between first and second test. 
All analyses were conducted with SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). 
 
Results 
Among the 38,340 men participating to the intervention arm, 31,286 men had two 
PSA tests within two years and with an initial value below 4 ng/mL, a level widely taken as 
the upper limit of normal.  
The PSA level measured in the first test was significantly (p<0.0001 chi-square test) 
associated with age (Table 1). 
The association of baseline PSA value was also found for BMI (p<0.0001 chi-square 
test), for which lower PSA values were observed for obese patients (median 0.94 ng/ml 
among the 7,337 obese patients: BMI above 30 kg/m
2
) and for overweight men (median 1.06 
ng/ml among the 15,392 overweight patients: BMI between 25 and 30 kg/m
2
), as compared 
to men with normal BMI (median 1.11 ng/ml among the 7,880 patients with normal weight: 
BMI between 18.5 and 25 kg/m
2
). Tobacco smoking was also significantly associated with a 
lower PSA level at baseline (p<0.0001 chi-square test): the median PSA for current smokers 
was 1.01 ng/ml, for former smokers the median PSA was 1.01 ng/ml, as compared to never 
 5 
 
smokers which PSA level was 1.08 ng/ml. The effect of tobacco smoking was independent of 
BMI as in an linear regression of PSA value at baseline adjusted on BMI status, current 
smoker had on average 0.10 ng/ml (95%CI (-0.14, -0.07)) less than never smokers. Race was 
not significantly associated with PSA level at baseline (p=0.09 when comparing the six 
different ethnic groups and p=0.25 when comparing PSA levels between non-Hispanic white 
men versus non-Hispanic black men).  
The median duration between first and second test was 344 days (interquartile range 
[IQR]: 324; 365). From the first to second test, the median variation of PSA levels was 3.4% 
(IQR: -15%; +26%) indicating that for a quarter of men the PSA level at second test was 15% 
lower than at first test, and that for another quarter of men the PSA level at second test was 
26% higher than at first test (figure 1). 
In other words, for half of men, the change in PSA level between the first and the 
second test exceeded 20%. The variation in PSA value was not significantly associated with 
the delay between first and second test (p=0.36 GLM model), with age (p=0.16), with BMI 
(p=0.41) and with race (p=0.12). In terms of total variation, the PSA value varied either 
positively or negatively by an average of 18% between first and second test (interquartile 
range: 9.2%, 36.8%). 
In a multivariate model of the variation of PSA, older age was significantly associated 
with higher variation in PSA between first and second test. In addition the baseline value of 
PSA was strongly associated with total variation: lower initial value of PSA tended to be 
associated with greater total variation (table 2). 
2,781 prostate cancers were diagnosed during follow-up. Adjusting for age and initial 
PSA level, the risk of prostate cancer increased linearly with increasing PSA level at second 
test, with an odds ratio (OR) of 1.079 (95% CI 1.058-1.101) for each % increase in PSA level. 
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Table 3 shows the distribution of prostate cancer cases by variation of PSA level between 
first and second test. 
However, the variation in PSA was not associated with a higher Gleason score 
 ?ƉA? ? ? ? ?ĨŽƌůĞǀĞůǀĂƌŝĂƚŝŽŶƐŝŶĐĂŶĐĞƌŽĨ'ůĞĂƐŽŶƐĐŽƌĞA? ?ǀƐA? ?ŝŶĂůŽŐŝƐƚŝĐƌĞŐƌĞƐsion model 
adjusting for age and baseline PSA value). Compared to men with decrease or no change in 
PSA level over time, men with variations in level of 50% or more had a 4.2 (95% CI 2.8-6.2) 
greater risk to be diagnosed with a lesion having a Gleason score of 5 or less, a 2.0 (95% CI 
1.7- ? ? ? ?ŐƌĞĂƚĞƌƌŝƐŬƚŽďĞĚŝĂŐŶŽƐĞĚǁŝƚŚĂĐĂŶĐĞƌŽĨ'ůĞĂƐŽŶƐĐŽƌĞA? ?ďƵƚďĞůŽǁ ? ?ĂŶĚĂ
2.5 (95% CI 1.7- ? ? ? ?ŐƌĞĂƚĞƌƌŝƐŬƚŽďĞĚŝĂŐŶŽƐĞĚǁŝƚŚĂĐĂŶĐĞƌŽĨ'ůĞĂƐŽŶƐĐŽƌĞA? ? ? 
 
Discussion 
In one quarter of men with an initial PSA level less than 4 ng/mL, the level of a 
second PSA test performed on average one year later will be 20% lower, while for another 
quarter of men it will be 20% higher. While an increase in PSA level over time is associated 
with increased risk of prostate cancer, this association seems stronger for cancers of low 
Gleason score than for potentially more aggressive cancers. 
Boddy et al (2004) found in a series of 14 patients with benign prostatic biopsy and 
an initial PSA level below 4 ng/ml that the coefficient of variation of PSA was 14.1% 
12
. This 
figure is in line with our observation of an average coefficient of variation of 18.8%. 
A study focusing on PSA in relation to prostate volume found a yearly increase of PSA 
associated with PSA baseline value 
13
. While this report also found that the initial PSA level 
was an important factor, lower values were found to be associated with greatest variability. 
As Nichols et al (2012) used a different metric, the variation of PSA expressed as the 
difference in ng/ml per year, this metric was also applied to the PLCO dataset. However, the 
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findings remained unchanged with greater variation observed for the lower values of PSA at 
baseline. 
The initial PSA level was lower among obese and overweight men as reported in 
previous studies 
14,15
. In a study conducted in healthy men, free of prostate cancer, in 
Washington State, the geometric mean of PSA was 1.18, 1.12, and 0.94 for respectively 
normal, overweight and obese men 
14
. These levels of PSA by obesity status were also 
observed in this report. Wright et al reported that this association was however partially 
confounded with use of aspirin and non-steroidal anti-inflammatory drugs (NSAID) 
14
 which 
we could not evaluate in these data. We found that further changes in PSA over time were 
not associated with BMI level. 
Ethnicity is a factor associated with access to care and PSA testing is not spared from 
this inequality. In men with high PSA level, fewer non-Hispanic black men would conduct a 
repeated PSA test as compared to non-Hispanic white, in particular for those not in the age 
eligible for Medicare (less than 65) 
16
. However, when adjusting for age, baseline PSA and 
other factors, we did not found an association between change in PSA level and ethnicity as 
we could have expected that if non-Hispanic black men had fewer tests. As the PLCO study 
was restricted to men with two tests within two years and in the intervention arm of the 
PLCO study, and because PLCO study is a randomized trial, these could have selected the 
populations and reduced the impact of inequality of access to care by ethnic group. 
In the PCPT study, the level of PSA was further related with severity of the disease. 
Prostate cancer with a Gleason score of 7 or above were 40 % with a PSA above 4 ng/ml, as 
compared to 21 % for those with a Gleason score below 7. Even among those with a PSA 
below 4 ng/ml this association remained: 60 % of prostate cancer with a Gleason score of 7 
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or above being above 2 ng/ml as compared to 35% of those with a Gleason score less than 7 
1
. 
While we demonstrated that an elevated PSA provided an increasing risk of prostate 
cancer, the results from the PLCO study are in contradiction with the PCPT study, as we 
found that the initial level of PSA was unrelated to the severity of disease. 
Our study has potential limitations. First, a strict selection was used with only men 
with two tests within two years and no initial value of PSA greater than 4ng/ml. However, 
this represented 81.6% of the initial sample and therefore a strong bias is unlikely. A 
contamination by previous PSA tests could have created a bias in the evaluation of PSA 
variation, however the PLCO study excluded men with more than one PSA blood test in the 
previous three years. The PLCO study design adds also some limitation but brings major 
advantages for the present research. On one hand, participants to the PLCO study 
constitutes, as for any prospective study, a selected population with higher levels of 
education, lower history of chronic disease. Hence, variations of PSA between two tests 
could be slightly different in the general population. On the other hand, this design enables 
to investigate variation of PSA in a homogeneous population which received regular 
opportunity to take a PSA test. Other design conducted in the population would have been 
confronted to greater biases such a self-selection for the number of tests, intervals between 
tests, ĂůůƚŚĞƐĞƌĞůĂƚĞĚƚŽŝŶĚŝǀŝĚƵĂů ?ƐĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐƐƵĐŚĂƐƉĞƌĐĞƉƚŝŽŶŽĨƌŝƐŬ ?ŚĞĂůƚŚƐƚĂƚƵƐ ?
socio-economic level, etc. 
Our study supports the idea that PSA testing cannot be considered as a perfect 
marker of prostate cancer risk. This weakness is inherent to PSA as it measures a 
characteristic of the prostate which is the release of an antigen in the blood. PSA is also a 
good marker of other prostate features, such as prostatic volume 
17
 and inflammation 
18
. 
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Variation in PSA was not associated with higher Gleason score. This observation is in 
agreement with the lack of effectiveness of PSA Velocity above PSA alone which was 
illustrated by several studies 
19
. 
PSA alone at low values does not seem to be a good indicator of risk of prostate 
cancer as it does not help to differentiate aggressive versus indolent tumors. The use of PSA 
density has been suggested to provide further discriminant properties 
20
, but this measure is 
still not demonstrated as capable of identifying aggressive tumors. 
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Figure legends 
Figure 1. Distribution of the percentage variation of PSA level between first and second 
measurement in the PLCO study. The blue curve is a kernel density estimation with 
bandwidth=0.6. 
 
E. Figure(s): #1
Click here to download high resolution image
Table 1. Distribution of men with an initial PSA value below 4 ng/ml by age and 
PSA value at entry in the intervention arm of the PLCO study. 
 
           Age group 
PSA value     
 UHI 60-64 65-69  Total 
PSA <0.5    n 1,790 1,527 911 461 4,689 
                % 17.0% 15.3% 13.0% 12.4%  
PSA 0.5-1       n 3,943 3,259 2,008 996 10,206 
                % 37.4% 32.6% 28.6% 26.7%  
PSA 1-1.5       n 2,228 2,076 1,387 698 6,389 
                % 21.1% 20.8% 19.8% 18.7%  
PSA 1.5-2       n 1,161 1,212 1,005 527 3,905 
                % 11.0% 12.1% 14.3% 14.1%  
PSA 2-3         n 983 1,266 1,098 668 4,015 
                % 9.3% 12.7% 15.6% 17.9%  
PSA 3-4         n 441 647 612 382 2,082 
                % 4.2% 6.5% 8.7% 10.2%  
Total n 10,546 9,987 7,021 3,732 31,286 
 
F. Table(s): #1
  
 
 
Table 2. Predictors of the percentage variation in PSA level between first and 
second test in the PLCO study. Results from a multivariate linear model 
adjusting for all variables 
 
Parameter  Estimate 95% confidence 
limits  
p-value 
Intercept  0.021 -0.109, 0.151 0.752 
     
Age  Reference - - 
60 - 64 0.092 0.040, 0.144 0.0005 
65 - 69 0.103 0.046, 0.161 0.0004 
 0.145 0.074, 0.216 <0.0001 
    
BMI (kg/m2) 0 - 18.5 0.105 -0.262, 0.471 0.575 
18.5 - 25 Reference - - 
25 - 30 0.018 -0.033, 0.069 0.489 
 -0.004 -0.065, 0.056 0.895 
    
Smoking status Never smoked Reference - - 
Former smoker -0.0008 -0.046, 0.044 0.972 
Current smoker 0.048 -0.024, 0.120 0.194 
    
Race White, Non-Hispanic Reference - - 
American Indian 0.446 -0.008, 0.900 0.054 
Asian 0.006 -0.100, 0.112 0.912 
Black, Non-Hispanic 0.018 -0.089, 0.124 0.747 
Hispanic -0.009 -0.158, 0.140 0.903 
Pacific Islander 0.263 -0.016, 0.542 0.065 
Missing -0.077 -1.054, 0.901 0.878 
    
Delay (per 1 year) between first and second 
PSA 
0.050 -0.069, 0.169 0.412 
    
Level of first PSA < 0.5 0.524 0.459, 0.589 <0.0001 
F. Table(s): #2
  
 
(ng/ml) Ref: 0.5 - 1 Reference - - 
1 - 1.5 -0.060 -0.119, -0.001 0.045 
1.5 - 2 -0.114 -0.184, -0.045 0.001 
2 - 3 -0.128 -0.197, -0.059 0.0003 
3 - 4 -0.136 -0.225, -0.047 <0.0001 
    
 
Table 3. Distribution of prostate cancer cases according to PSA levels 
 
PSA (ng/mL) Men without prostate 
cancer (percentage ) 
Gleason < 7 
(percentage) 
*OHDVRQ
(percentage) 
Total 
< 0.5 4, 643 (16.29) 19 (1.22) 26 (2.17) 4,688 
ref: 0.5 - 1 9,924 (34.81) 142 (9.13) 136 (11.37) 10,202 
1 - 1.5 5,914 (20.75) 245 (15.75) 226 (18.9) 6,385 
1.5 - 2 3,398 (11.92) 275 (17.67) 228 (19.06) 3,901 
2 - 3 3,208 (11.25) 473 (30.4) 324 (27.09) 4,005 
3 - 4 1,418 (4.97) 402 (25.84) 256 (21.4) 2,076 
Total 28,505 1,556 1,196 31,257 
Missing PSA    29 
 
 
F. Table(s): #3
